Novel greenly synthesized titanium dioxide nanoparticles compared to liposomes in drug delivery: in vivo investigation on Ehrlich solid tumor model.

AIMS: In a previous work, a pure crystalline titanium dioxide nanoparticles (TiO2NPs) were synthesized by green synthesis technique using Aloe vera leaves extract as reducing agent. In this work, we are aiming to investigate the potential of the novel greenly synthesized TiO2NPs as a nano-drug delivery system for the anticancer drug, doxorubicin (Dox). MAIN METHODS: The cytotoxicity of the synthesized TiO2NPs was tested on two cell lines; normal human skin fibroblasts (HSF) and breast adenocarcinoma cells (MCF-7). Then, Dox was loaded to both TiO2NPs (Dox- TiO2NPs) and liposomes (Dox-Lip). The loaded nanoparticles were characterized by TEM, FTIR, encapsulation efficiency, particle size and zeta potential measurement. Moreover, in vitro drug release was studied. Ehrlich tumor-bearing mice were used to study the anticancer activity of Dox- TiO2NPs, Dox-Lip, and aqueous Dox solution. Tumor volume, survival rate, and histopathological alterations were compared in all groups. KEY FINDINGS: Dox was successfully loaded to both liposomes and TiO2NPs with an encapsulation efficiency of 77% and 65%, respectively. The particle size of Dox-TiO2NPs, and Dox-Lip was 14.53 nm, and 103 nm, respectively. The cumulative Dox released from TiO2NPs and liposomes after 4 h was 18 and 46%, respectively.Dox-Lip and Dox-TiO2NPs resulted in the highest degree of tumor growth inhibition with 100% and 83% of treated animals remained alive, respectively. SIGNIFICANCE: The greenly synthesized TiO2NPs were proved to be as effective as liposomes in enhancing the anticancer activity of Dox.

Intralesional vitamin D3 versus new topical photodynamic therapy in recalcitrant palmoplanter warts Randomized comparative controlled study.

BACKGROUND: Recalcitrant palmoplanter warts represent a therapeutic challenge. Side effects of local destructive methods necessitates the need for other less morbid modalities. Recently immunotherapy as well as light based devices and lasers have emerged as therapeutic approaches. AIM OF THE STUDY: To compare between the safety and efficacy of intralesional vitamin D3 injection and photodynamic therapy (PDT) using eosin in treatment of recalcitrant palmoplanter warts. PATIENTS AND METHODS: Prospective, randomized, controlled comparative study. Fifty -six patients with recalcitrant palmoplanter warts were randomly divided into 3 groups. Group A was injected with intralesional vitamin D3. Group B was subjected to PDT using eosin loaded in trasferosomes as a photosensitizer. Group C is the control group. Clinical improvement was assessed by photographic records and dermoscopic assessment, at baseline, before each session and after completion of treatment. Patients were followed up for 6 months after cure to detect recurrence. RESULTS: Group A and B showed complete clearance in 88.89 % and 86.36 % respectively compared to 18.75 % in the control group. These results were statistically significant (P value<0.001). No side effects were reported except for pain during injection in group A. CONCLUSION: In the current study, both vitamin D3 and PDT using Eosin are safe, highly effective and well tolerated modalities in treatment of viral warts.

PEGylated lipid nanocarrier for enhancing photodynamic therapy of skin carcinoma using curcumin: in-vitro/in-vivo studies and histopathological examination.

The use of (PEG)-grafted materials has a positive impact on drug delivery. In this study we designed PEGylated lipid nanocarriers (PLN) loaded with curcumin (Cur) to target skin cancer by photodynamic therapy. Cur is a polyphenolic compound having vast biological effects masked due to its low aqueous solubility. PLN were prepared using Tefose 1500 with different surfactants. PLN3, containing Tween 80, had the smallest particle size (167.60 ± 15.12 nm), Z = - 26.91 mV and, attained the highest drug release (Q24 = 75.02 ± 4.61% and Q48 = 98.25 ± 6.89%). TEM showed spherical, well-separated nanoparticles. The dark and photo-cytotoxicity study on a human skin cancer cell line (A431) revealed that, at all tested concentrations, the viability of cells treated with PLN3 was significantly lower than those treated by Cur suspension and, it decreased upon irradiation by blue light (410 nm). The amount of Cur extracted from the skin of mice treated by PLN3 was twice that of mice treated by aqueous drug suspension, this was confirmed by the increase in fluorescence intensity measured by confocal laser microscopy. Histopathological studies showed that PLN3 could extend Cur effect to deeper skin layers, especially after irradiation. This study highlights the possible efficacy of curcumin-loaded PEGylated lipidic nanoparticles to combat skin cancer by photodynamic therapy.

Topical photodynamic therapy of tumor bearing mice with meso-tetrakis (N-methyl-4-pyridyl) porphyrin loaded in ethosomes.

Photodynamic therapy is a clinically approved procedure for the treatment of neoplastic and other non-malignant diseases. Meso-tetrakis(N-methyl-4-pyridyl)porphyrin (TMPyP) is a photosensitizing agent which has been used in many applications. However, the use of TMPyP topically is limited due to its hydrophilicity. To overcome this problem, TMPyP was loaded in ethosomes. Three ethosomal formulae (A), (B) and (C) were prepared and characterized. Preparation (A) was chosen to be used in the in vitro and in vivo study, having the greatest encapsulation efficiency, the smallest size and the highest cumulative release percentage. The results of in vitro permeation study revealed that the ethosomal TMPyP was superior to the drug in the free form with permeation flux (3.92 µg cm-2 h-1). In the in vivo animal study done on Swiss albino mice, after 19 days of Ehrlich tumor implantation, the group treated with the ethosomal preparation showed significantly smaller tumor size (143.28 ±â€¯13.2 mm3) compared to the group treated with the free TMPyP (219 ±â€¯11.9 mm3). It showed also significant longer survival time (21 days) compared to that treated with the free drug (18.2 ±â€¯1.2 days). Based on the obtained results, transdermal delivery of TMPyP was potentiated by incorporating it in ethosomes.